Peptides DB
Research-centric peptide and protocol reference hub
Study 16 of 47NAD+ (Nicotinamide Adenine Dinucleotide) literatureScience (New York, N.Y.)Top journal2026

Bacteria sense virus-induced genome degradation via methylated mononucleotides.

Bacteria have developed a defense system called Metis that senses phage-induced genome degradation, potentially halting infection through NAD+ depletion.

Read at Science (New York, N.Y.)Add to compare

Where it sits

this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpus
17
Preclinical · this one
23
Observational
1
Open-label
1
Randomised
5
Reviews

Summary and findings

This study investigates the bacterial defense system Metis, which senses phage-induced genome degradation via the modified nucleotide m6dAMP. The research highlights how Metis activates an NAD+ diphosphatase, leading to NAD+ depletion and halting phage infection. No therapeutic claims are made.

How much of this paper we could read: title only (0.20). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Science (New York, N.Y.) supplied them

Phages often degrade the genome of their bacterial host to individual nucleotides. Here we describe Metis, a bacterial defense system that directly senses phage-mediated host genome degradation. Metis aborts phage infection once it detects the modified mono-nucleotide m6dAMP. As methylation of deoxyadenosines usually occurs on the DNA polymer, accumulation of m6dAMP signals that the host genome has been degraded. In type I Metis, sensing of m6dAMP activates an NAD+ diphosphatase, leading to NAD+ depletion and cessation of the infection process; while the effector in type II Metis is a membrane-spanning protein whose toxicity is triggered in response to the modified mono-nucleotide. We further show that Metis defense depends on endogenous DNA methylases, and that phages can escape Metis via mutations that inactivate host genome degradation.

Background

The paper addresses the biological question of how bacteria sense viral infections, specifically through the degradation of their genomes. Prior research has established that bacteria have mechanisms to respond to viral threats, but the specific molecular pathways involved remain unclear. This study is significant as it explores the role of methylated mononucleotides in this detection process, potentially revealing new insights into bacterial defense mechanisms.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Elsewhere in the NAD+ (Nicotinamide Adenine Dinucleotide) corpus

CBioactive vitamin E-NAD<sup>+</sup> conjugate nanoparticles for osteoarthritis management via simultaneous suppression of inflammation and oxidative stress.Biomaterials · 2026 · Not reported in abstract.AnimalBNAD metabolism mediates a sex-specific protection against early life infectionsbiorxiv-preprint · 2026 · Higher birth NAD levels in females were associated with reduced infection burdens during the first 3 years of life.HumanBControl-referenced bacterial bioluminescence reveals a two-axis salivary response phenotype in benign and malignant breast disease.Talanta · 2026 · n=200 · Not reported in abstract.HumanBGenetic modulation of NAD(P)H homeostasis reveals distinct redox-coupled metabolic vulnerabilities.Nature metabolism · 2026 · Not reported in abstract.HumanDA context-dependent framework for targeting NAD metabolism in cancer.Cell metabolism · 2026reviewBPart 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injectionsbiorxiv-preprint · 2026 · 9.97% average daily increase in NAD+ for 100 mg IM.Human